Skip to main content

Table 3 Adverse eventsa

From: A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma

AE term

All grades

Grade ≥ 3

 

n (%)

n (%)

Fatigue

21 (68)

3 (10)

Hypertension

20 (65)

3 (10)

Anorexia

19 (61)

2 (6)

Proteinuria

14 (45)

4 (13)

Diarrhea

13 (42)

0

AST increased

13 (42)

7 (23)

PPES

12 (39)

1 (3)

Thrombocytopenia

10 (32)

1 (3)

ALT increased

9 (29)

5 (16)

Bilirubin increased

8 (26)

3 (10)

Skin rash

6 (19)

0

Peripheral edema

6 (19)

0

Amylase increased

5 (16)

0

Hoarseness

5 (16)

0

Nausea

3 (10)

0

Abdominal pain

3 (10)

0

Dysgeusia

2 (6)

0

Mucositis oral

2 (6)

0

  1. aAEs were collected up to 30 days following the final use of LEN. Percentage was calculated as the number of patients with AE divided by the whole patient population enrolled (N = 31)
  2. AST aspartate aminotransferase, PPES palmar-plantar erythrodysesthesia, ALT alanine aminotransferase